Foundation Medicine Inc. announced Monday a multi-year collaboration with pharmaceutical giant AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. Cambridge-based Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. AstraZeneca, an Anglo-Swedish company, has a big presence in Greater Boston.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help